Suppr超能文献

光动力疗法使成熟的角膜淋巴管消退。

Regression of mature lymphatic vessels in the cornea by photodynamic therapy.

机构信息

Department of Ophthalmology, University of Cologne, , Cologne, Germany.

出版信息

Br J Ophthalmol. 2014 Mar;98(3):391-5. doi: 10.1136/bjophthalmol-2013-303887. Epub 2014 Jan 10.

Abstract

BACKGROUND

Corneal (lymph) angiogenesis is a predominant risk-factor for immune rejection after transplantation. Techniques to regress pre-existing pathological corneal lymphatic vessels prior to transplantation are missing so far. Therefore we analysed the possibility to regress corneal lymphatic vessels by photodynamic therapy (PDT), after intrastromal verteporfin injection.

METHODS

Combined hemangiogenesis and lymphangiogenesis was induced in female BALB/c mice using the murine model of suture-induced inflammatory neovascularisation. Thereafter, the treatment group received an intrastromal injection of verteporfin (controls: phosphate buffered saline (PBS)) followed by PDT. Corneas were excised at different time points (1 day, 5 days and 10 days) after PDT and corneal whole mounts were stained with CD31 and LYVE-1 to quantify hemangiogenesis and lymphangiogenesis.

RESULTS

Whereas blood vessels showed no significant reduction after PDT, lymphatic vessels could significantly be reduced with PDT after intrastromal verteporfin injection: 1 day after PDT, lymphatic vessels were reduced by 62% (p=0.20). After 5 days and 10 days, lymphatic vessels were reduced by 51% and 48% (p<0.001), respectively.

CONCLUSIONS

This study for the first time shows that PDT after corneal intrastromal verteporfin injection can selectively regress lymphatic vessels. This may become a new 'preconditioning strategy' to reduce pre-existing corneal lymphatic vessels prior to transplantation and thereby reduce allograft rejection in high-risk patients.

摘要

背景

角膜(淋巴)血管生成是移植后免疫排斥的主要风险因素。目前缺乏在移植前消退预先存在的病理性角膜淋巴管的技术。因此,我们分析了经皮腔内血管成形术(PDT)在经皮腔内维替泊芬注射后消退角膜淋巴管的可能性。

方法

使用缝线诱导的炎症性新生血管化的小鼠模型诱导雌性 BALB/c 小鼠的血管生成和淋巴管生成。此后,治疗组接受维替泊芬(对照组:磷酸盐缓冲盐水(PBS))的间质内注射,然后进行 PDT。在 PDT 后不同时间点(1 天、5 天和 10 天)切除角膜,并对角膜全层进行 CD31 和 LYVE-1 染色,以量化血管生成和淋巴管生成。

结果

尽管血管在 PDT 后没有明显减少,但经皮腔内维替泊芬注射后的淋巴管可以通过 PDT 显著减少:在 PDT 后 1 天,淋巴管减少了 62%(p=0.20)。在 5 天和 10 天,淋巴管分别减少了 51%和 48%(p<0.001)。

结论

这项研究首次表明,经皮腔内维替泊芬注射后的 PDT 可以选择性消退淋巴管。这可能成为一种新的“预处理策略”,以减少移植前预先存在的角膜淋巴管,从而降低高危患者的同种异体移植排斥反应。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验